Shopping Cart
Remove All
Your shopping cart is currently empty
Ladiratuzumab (Synonyms: hLIV22)
Catalog No. T77415 Copy Product Info
🥰Excellent
LadiratuzumAb (hLIV22) is a humanized monoclonal antibody targeting LIV-1/ZIP6.LadiratuzumAb is a naked antibody to SGN-LIV1A and is capable of synthesizing an antibody-activated molecule coupling (ADC), SGN-LIV1A.LadiratuzumAb can be used for the prevention and treatment of breast cancer.
Ladiratuzumab
Copy Product Info🥰Excellent
Catalog No. T77415
Synonyms hLIV22
LadiratuzumAb (hLIV22) is a humanized monoclonal antibody targeting LIV-1/ZIP6.LadiratuzumAb is a naked antibody to SGN-LIV1A and is capable of synthesizing an antibody-activated molecule coupling (ADC), SGN-LIV1A.LadiratuzumAb can be used for the prevention and treatment of breast cancer.
Ladiratuzumab
Cas No. 1629760-28-6
Customer service consultation
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $263 | - | In Stock | |
| 5 mg | $538 | - | In Stock | |
| 10 mg | $872 | - | In Stock | |
| 25 mg | $1,290 | - | In Stock | |
| 50 mg | $1,730 | - | In Stock |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:98.2% (SEC-HPLC)
Appearance:Liquid
Color:Transparent
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | LadiratuzumAb (hLIV22) is a humanized monoclonal antibody targeting LIV-1/ZIP6.LadiratuzumAb is a naked antibody to SGN-LIV1A and is capable of synthesizing an antibody-activated molecule coupling (ADC), SGN-LIV1A.LadiratuzumAb can be used for the prevention and treatment of breast cancer. |
| Synonyms | hLIV22 |
| Reactivity | Human |
| Verified Activity | Immobilized Human LIV-1 Protein at 2 μg/mL (30 μL/well) can bind Ladiratuzumab. The EC50 is 5.145 ng/mL.  |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | LIV-1/SLC39A6 |
| Molecular Weight | 146.1 kDa |
| Cas No. | 1629760-28-6 |
| Isotype | Human IgG1 kappa |
| Recommended Isotype Control |
| Storage | -20°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
Citations
Calculator
Keywords
Preview
Related Tags: buy Ladiratuzumab | purchase Ladiratuzumab | Ladiratuzumab cost | order Ladiratuzumab | Ladiratuzumab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.